創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/11/05 GEM125 Antiinflammatory and antifibrotic mono-unsaturated fatty acid (MUFA) NAFLD, NASH Oral Small molecules Preclinical MUFA (C16:1) is more capable of entering and improving function of endothelial cells and increasing cellular fluidity. Directly targets liver fat accumulation while also reducing LDL, increasing HDL and reducing Triglycerides. Targets F0-F2 Fibrosis, approximately 60%-70% of NASH patient population. More stable and less susceptible to oxidize/polymerize than Eicosapentanoic Acid derivatives. Can be used alongside drugs with alternate mechanisms of action or unwanted effects. 問合せ
19/11/05 GEM124 Antiatherosclerotic and antiinflammatory mono-unsaturated fatty acid (MUFA) Refer to Note Oral Small molecules Preclinical Indication:
Atherosclerosis (future indications: primary prevention of Heart Attack, Stroke and Death and Secondary Prevention of Myocardial Infarction in Europe)

Note:
MUFA (C16:1) is more capable of entering and improving function of endothelial cells and increasing cellular fluidity. Developed to target vulnerable, high risk plaques. Preclinical data shows superior plaque reduction over EPA. Directly targets fats while also reducing LDL, increasing HDL and reducing Triglycerides. More stable and less susceptible to oxidize/polymerize than Eicosapentanoic Acid derivatives.

問合せ
19/10/29 GEM123 miRNA targeting cancer stem cells colon cancer i.v. Nucleic acid
Preclinical GEM123 suppressed the stemness of cancer cells by inhibiting KLF5 expression, and provoked apoptosis and cycle arrest through the downregulation of TFDP1and MDM2 expressions.
GEM123 also inhibited tumor growth with no apparent side effect in mouse model.
問合せ
19/10/29 GEM122 Natural Killer T (NKT) cell-mediated anti-tumor responses Solid cancer i.v. Cell Therapy
Phase 1 GEM122 shows its anti-tumor activity by activating endogenous NKT cells.
Activated NKT cells strongly enhance both innate and acquired immune systems, induce the long-term immune memory and promote accumulation of TILs (tumor infiltrating lymphocytes) in tumor sites.
GEM122 consists of a novel NKT ligand and a novel APC.
The novel NKT ligand shows much stronger NKT activity than the previous NKT ligand, α-Galactosylceramide and by using the novel APC, the cellular product can be manufactured efficiently as well.
問合せ
19/10/23 GEM121 Modified phytic acid (inositol hexaphosphate: IP6) Cancer Oral Small molecule
Preclinical · Demonstrated selective anti-cancer effects including apoptosis and inhibition of Akt activation.
· In vivo study using mice with adult T-cell leukemia showed reduction of the size of the cancer.
問合せ
19/10/23 GEM120 Inhibition of membrane binding of Pr55Gag HIV i.v. Small molecule
Preclinical · Inhibited the membrane localization of Pr55Gag and stopped budding of HIV virus.
· Captures HIV in immune cells and induces apoptosis of the HIV-infected immune cells.
問合せ
19/10/23 GEM119 Inactivation of end-product of lipid peroxidation Cerebral Infarction i.v. Small molecule
Preclinical · Showed more potent 4-hydroxynonenal - quenching activity compared with carnosine or histidine hydrazide (HH) at 30min incubation.
· GEM119 ( ip administration) rescued the hippocampal CA1 cell death of transient cerebral ischemia model of Mongolian gerbil whereas HH did not.
問合せ
19/10/23 GEM118 Suppression of TGF-b/Smad and related signaling Systemic sclerosis Oral Small molecule
Preclinical · Inhibited phosphorylation of Smad3 and expression of Col1a2, FN1 and CTGF stimulated by TGF-b in cultured human dermal fibroblasts.
· Ameliorated bleomycin-induced skin fibrosis in both preventative and curative mouse model.
問合せ
19/10/16 GEM117 Induction of apoptosis in adipocyte Lipolysis, non-surgical fat reduction, Diabetes Refer to Note Small molecule
Phase 2a Route:
Subcutaneous

Note:
· GEM117 specifically induce apoptosis on local injection site adipocyte · Phase 1 showed great safety without drug related SAE in 40 healthy volunteers · In pre-clinical study
- Better efficacy on local fat reduction and less side effects that surpass the current surgical liposuction and other non-surgical products.
- Has benefit effects on lipid and glucose metabolism and improves the indicator of diabetes
問合せ
19/10/16 GEM116 Increase in lipolysis, fat and energy metabolism Obesity, Diabetes, NAFLD/NASH Oral Small molecule
Phase 2 ·GEM116 demonstrated the safest profile in its clinical phase 2 study with more than 200 patients without any drug related AE or SAE and potentially lower CVD risk seen by other competitors in the market
· Around 30% of subjects lost at least 5% body weight in 12 weeks, GEM116 shows around 5% body fat lost, lower TC by around 12mg/dL, and lower LDL by around 6 mg/dL
·Pre-clinical study shows GEM116 has the potential to treat NAFLD/NASH via reducing liver fibrosis by aroud 40% .
問合せ